• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.

作者信息

Antonelli Alberto, Giani Tommaso, Di Pilato Vincenzo, Riccobono Eleonora, Perriello Gabriele, Mencacci Antonella, Rossolini Gian Maria

机构信息

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.

出版信息

J Antimicrob Chemother. 2019 Aug 1;74(8):2464-2466. doi: 10.1093/jac/dkz156.

DOI:10.1093/jac/dkz156
PMID:31318973
Abstract
摘要

相似文献

1
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.在对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌中表达的KPC-31与相关检测问题有关。
J Antimicrob Chemother. 2019 Aug 1;74(8):2464-2466. doi: 10.1093/jac/dkz156.
2
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.单独使用头孢他啶/阿维巴坦或与氨曲南联合使用治疗对黏菌素耐药且产碳青霉烯酶的肺炎克雷伯菌。
J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. doi: 10.1093/jac/dkx393.
3
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.头孢他啶-阿维巴坦对一组碳青霉烯类耐药肠杆菌科挑战株的活性：OmpK36 L3 改变和具有头孢他啶水解活性的β-内酰胺酶导致 MIC 值升高。
Int J Antimicrob Agents. 2020 Jul;56(1):106011. doi: 10.1016/j.ijantimicag.2020.106011. Epub 2020 May 15.
4
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
5
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.巴西住院患者血流感染碳青霉烯类耐药肺炎克雷伯菌的新型β-内酰胺/β-内酰胺酶抑制剂组合的药敏评估。
J Glob Antimicrob Resist. 2024 Sep;38:247-251. doi: 10.1016/j.jgar.2024.06.007. Epub 2024 Jun 25.
6
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.鉴定头孢他啶-阿维巴坦和亚胺培南-雷利巴坦对碳青霉烯类耐药肠杆菌科的活性谱和治疗窗。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00642-17. Print 2017 Sep.
7
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
8
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.头孢他啶-阿维巴坦耐药肺炎克雷伯菌临床分离株的分子分析。
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6. doi: 10.1016/j.cmi.2021.03.001. Epub 2021 Mar 26.
9
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
10
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.产KPC-3型肺炎克雷伯菌分离株中头孢他啶-阿维巴坦耐药性的首次报告
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.

引用本文的文献

1
Diverse evolutionary trajectories of carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance.碳青霉烯酶的多样进化轨迹：揭示氨基酸取代对β-内酰胺敏感性的影响以及阿维巴坦在耐药性产生中的作用
mSystems. 2025 Apr 22;10(4):e0018425. doi: 10.1128/msystems.00184-25. Epub 2025 Mar 11.
2
Evaluation of three commercial lateral flow immunoassays for the detection of KPC, VIM, NDM, IMP and OXA-48-like carbapenemases.用于检测KPC、VIM、NDM、IMP和OXA-48样碳青霉烯酶的三种商用侧向流动免疫测定法的评估。
J Antimicrob Chemother. 2024 Oct 1;79(10):2724-2727. doi: 10.1093/jac/dkae262.
3
Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime-Avibactam in an ST11 Strain.
在一株ST11菌株中鉴定出一种新型KPC变体KPC-204，其对碳青霉烯类和头孢他啶-阿维巴坦均具有耐药性。
Microorganisms. 2024 Jun 13;12(6):1193. doi: 10.3390/microorganisms12061193.
4
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.哥伦比亚首次报道产碳青霉烯酶变种导致头孢他啶-阿维巴坦耐药：引入 KPC-197。
Microbiol Spectr. 2024 Jun 4;12(6):e0410523. doi: 10.1128/spectrum.04105-23. Epub 2024 May 3.
5
Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test.快速 CAZ/AVI NP 试验检测肠杆菌科中头孢他啶/阿维巴坦的药敏/耐药性。
Emerg Infect Dis. 2024 Feb;30(2):255-261. doi: 10.3201/eid3002.221398.
6
carbapenemase variants: the new threat to global public health.碳青霉烯酶变体：对全球公共健康的新威胁。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8.
7
Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Carbapenemase-Producing Infections: A Retrospective, Observational, 2-Center Clinical Study.产碳青霉烯酶的头孢他啶/阿维巴坦耐药感染的临床特征及转归：一项回顾性、观察性、双中心临床研究
Open Forum Infect Dis. 2023 Jun 30;10(7):ofad327. doi: 10.1093/ofid/ofad327. eCollection 2023 Jul.
8
Laboratory automation, informatics, and artificial intelligence: current and future perspectives in clinical microbiology.实验室自动化、信息学和人工智能：临床微生物学的当前和未来展望。
Front Cell Infect Microbiol. 2023 Jun 27;13:1188684. doi: 10.3389/fcimb.2023.1188684. eCollection 2023.
9
Resistance to Ceftazidime/Avibactam in KPC-Producing Isolates: A Real-Life Observational Study.产KPC菌株对头孢他啶/阿维巴坦的耐药性：一项真实世界观察性研究。
Antibiotics (Basel). 2023 Apr 27;12(5):820. doi: 10.3390/antibiotics12050820.
10
Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing in ICU Setting: We Are What We Are Treated with?产碳青霉烯酶肺炎克雷伯菌（KPC） ICU 感染患者：我们用什么药物治疗，就会变成什么样？
Int J Mol Sci. 2023 Mar 1;24(5):4767. doi: 10.3390/ijms24054767.